Press Release: August 31, 2004
AuRx, Inc. announces tentative approval by the Mexican Ministry of Health to conduct Phase 3 Trials for Theraherp

AuRx, Inc. announced the tentative approval by the Mexican Ministry of Health to conduct a confirmatory Phase 3 trial Theraherp. Theraherp, also known as ICP10?PK, is a recombinant used to cause the body to suppress lesions, as well as all other symptoms in those who are infected with genital herpes.

The trial will be a placebo-controlled, double-blinded multi-center trial in Mexico with a 6 month follow-up. The primary endpoint will be prevention of lesions. This trial is designed to confirm the efficacy found in the initial Phase I/II clinical trial carried out in Mexico City. In that trial, Theraherp was very well tolerated and recurrences of lesions were eliminated in 84% of the vaccinated patients for a full year, while all signs and symptoms were prevented in 44% of the patients for a full year. In patients having episodes there was a statistically significant reduction in the number of episodes relative to the previous year in the vaccinated group. These results are far superior to those obtained with currently available drugs.

AuRx expects the results from this Phase III trial to show efficacy comparable to the earlier data and will lead to approval of Theraherp for sale in Mexico.

AuRx, Inc. is a privately held company based in Maryland.

For Additional Information Contact:
Gary J. Calton, President AuRx., Inc.
500 J McCormick Drive
Glen Burnie, MD 21061
410-590-7610